Neural Cells for Neurodegenerative Diseases in Clinical Trials

N/ACitations
Citations of this article
22Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Neurodegenerative diseases (ND) are an entire spectrum of clinical conditions that affect the central and peripheral nervous system. There is no cure currently, with treatment focusing mainly on slowing down progression or symptomatic relief. Cellular therapies with various cell types from different sources are being conducted as clinical trials for several ND diseases. They include neural, mesenchymal and hemopoietic stem cells, and neural cells derived from embryonic stem cells and induced pluripotent stem cells. In this review, we present the list of cellular therapies for ND comprising 33 trials that used neural stem progenitors, 8 that used differentiated neural cells,and 109 trials that involved non-neural cells in the 7 ND. Encouraging results have been shown in a few early-phase clinical trials that require further investigations in a randomized setting. However, such definitive trials may not be possible given the relative cost of the trials, and in the setting of rare diseases.

Cite

CITATION STYLE

APA

Fan, Y., Goh, E. L. K., & Chan, J. K. Y. (2023, August 1). Neural Cells for Neurodegenerative Diseases in Clinical Trials. Stem Cells Translational Medicine. Oxford University Press. https://doi.org/10.1093/stcltm/szad041

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free